Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Olaparib
- DRUG Lenvatinib
- DRUG Standard of Care (SOC)
- DRUG MK-4280
Study Locations (20)
California
- Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 0054) — Bakersfield
- California Cancer Associates for Research & Excellence ( Site 0016) — Fresno
- Providence Medical Foundation ( Site 0087) — Fullerton
- The Angeles Clinic and Research Institute ( Site 0005) — Los Angeles
- UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0009) — Los Angeles
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0076) — Orange
- Stanford Cancer Center ( Site 0086) — Palo Alto
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0004) — San Francisco
- Providence Saint John's Health Center ( Site 0059) — Santa Monica
Florida
- Holy Cross Hospital, Michael & Dianne Bienes Comp Cancer Ctr ( Site 0022) — Fort Lauderdale
- Baptist MD Anderson Cancer Center ( Site 0083) — Jacksonville
- Mount Sinai Medical Center Comprehensive Cancer Center ( Site 0031) — Miami Beach
- Moffitt Cancer Center ( Site 0011) — Tampa
Georgia
- Emory School of Medicine ( Site 0013) — Atlanta
- Augusta University ( Site 0077) — Augusta
- Northwest Georgia Oncology Centers PC ( Site 0061) — Marietta
Arizona
- Arizona Cancer Center at UMC North ( Site 0018) — Tucson
Colorado
- University of Colorado Cancer Center ( Site 0021) — Aurora
Connecticut
- Yale Cancer Center ( Site 0014) — New Haven
District of Columbia
- Georgetown University Medical Center ( Site 0023) — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,500 participants |
| Start Date | 2018-08-21 |
| Est. Completion | 2043-08-04 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03486873
The ClinicalTrials.gov registry entry for NCT03486873 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 3,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 741 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 5 interventions — of which Pembrolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03486873 reports 20 study locations spanning 7 distinct geographic areas — top geographies include California, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03486873 about?
NCT03486873 is a clinical study titled "Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)". The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u...
What is the current status of trial NCT03486873?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 3,500 participants. The study started on 2018-08-21. Estimated completion is 2043-08-04.
What conditions does trial NCT03486873 study?
This clinical trial studies the following conditions: Solid Tumors, Hematologic Malignancies. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03486873?
The interventions under investigation include: Pembrolizumab (DRUG), Olaparib (DRUG), Lenvatinib (DRUG), Standard of Care (SOC) (DRUG), MK-4280 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03486873?
This trial is sponsored by Merck Sharp & Dohme, which has 741 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03486873 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.